Table 2.
OCT1 Expression According to Treatment Outcome of Imatinib
| Characteristics | High expression (n=81) (%) | Low expression (n=77) (%) | p value |
|---|---|---|---|
| Gender | |||
| Male | 52 (64) | 46(59) | 0.34 |
| Female | 29 (35) | 31 (40) | |
| CML Phase | |||
| CP | 68 (83) | 56 (72) | 0.145 |
| AP | 9 (11) | 11 (14) | |
| BC | 4 (4) | 10 (12) | |
| Sokal score | |||
| High | 11 (13) | 17 (22) | 0.048 |
| Intermediate | 25 (30) | 32 (41) | |
| low | 45 (55) | 28 (36) | |
| Hematological Response | 0.062 | ||
| Complete | 74 (91) | 63 (81) | |
| Partial | 7 (8) | 14 (18) | |
| Molecular Response | 30 (37) | 18 (23) | 0.05 |
| Complete | 32 (39) | 28 (36) | |
| Major | 19 (23) | 31 (40) | |
| Poor | |||
| Gleevec (mg/day) | 0.283 | ||
| 400 | 70 (86) | 63 (81) | |
| 600 or 800 | 11 (13) | 14 (18) | |
| Response to Therapy | 0.018 | ||
| Responder | 62 (76) | 46 (59) | |
| Non Responder | 19 (23) | 31 (40) | |
* Wilcoxon rank sum test applied; Fisher’s exact /Chi-squire test applied.